London, UK and Boston, MA, USA, 2 October 2015 – Heptares Therapeutics is delighted to announce that it was the winner of the Best UK Biotech Dealmaker Award at the OBN Annual Awards ceremony celebrating outstanding achievement in the UK life sciences sector, held last night in Oxford, UK.
The Best UK Dealmaker Award was given to Heptares in recognition of its deal with Sosei in February 2015, and the potential, in its new home as part of Sosei Group, for Heptares to flourish and continue to discover and develop new therapeutics to GPCR targets in a range of diseases.
This award celebrates the best deal in the last 15 months prior to the Award for a UK company with an estimated valuation of less than £1bn, and was judged by a panel of leading figures from the life sciences industry.
OBN is the Membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. www.obn.org.uk